- Vanda Pharmaceuticals press release ( NASDAQ: VNDA ): Q4 GAAP EPS of $0.12 beats by $0.04 .
- Revenue of $64.5M (-5.2% Y/Y) misses by $3.1M .
- 2023 Financial Guidance
- Given uncertainties surrounding the U.S. market for HETLIOZ ® for the treatment of Non-24 as a result of the ongoing HETLIOZ ® patent litigation, Vanda is unable to provide 2023 financial guidance at this time. Vanda will continue to evaluate its ability to provide financial guidance as the year progresses.
For further details see:
Vanda Pharmaceuticals GAAP EPS of $0.12 beats by $0.04, revenue of $64.5M misses by $3.1M